Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Up 6.1% in November

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 46,800 shares, a growth of 6.1% from the November 15th total of 44,100 shares. Based on an average daily trading volume, of 43,900 shares, the days-to-cover ratio is presently 1.1 days. Approximately 2.7% of the company’s stock are short sold.

Avenue Therapeutics Price Performance

Shares of Avenue Therapeutics stock opened at $1.80 on Monday. Avenue Therapeutics has a 1 year low of $1.60 and a 1 year high of $26.47. The firm has a market cap of $3.69 million, a price-to-earnings ratio of 0.10 and a beta of -0.20. The company has a 50-day moving average of $2.05 and a 200 day moving average of $2.67.

Hedge Funds Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC purchased a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned about 1.17% of Avenue Therapeutics as of its most recent SEC filing. 17.34% of the stock is currently owned by institutional investors.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.